- Home
- REPL vs MAX Comparison
REPL vs MAX Comparison
Compare REPL & MAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- MAX
- Stock Information
- Founded
- REPL 2015
- MAX 2014
- Country
- REPL United States
- MAX United States
- Employees
- REPL N/A
- MAX N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- MAX Industrial Machinery/Components
- Sector
- REPL Health Care
- MAX Industrials
- Exchange
- REPL Nasdaq
- MAX Nasdaq
- Market Cap
- REPL 547.0M
- MAX 551.1M
- IPO Year
- REPL 2018
- MAX 2020
- Fundamental
- Price
- REPL $9.73
- MAX $12.75
- Analyst Decision
- REPL Buy
- MAX Buy
- Analyst Count
- REPL 9
- MAX 6
- Target Price
- REPL $10.88
- MAX $17.00
- AVG Volume (30 Days)
- REPL 8.7M
- MAX 510.7K
- Earning Date
- REPL 11-07-2025
- MAX 10-29-2025
- Dividend Yield
- REPL N/A
- MAX N/A
- EPS Growth
- REPL N/A
- MAX N/A
- EPS
- REPL N/A
- MAX N/A
- Revenue
- REPL N/A
- MAX $1,123,093,000.00
- Revenue This Year
- REPL N/A
- MAX $27.56
- Revenue Next Year
- REPL N/A
- MAX $10.79
- P/E Ratio
- REPL N/A
- MAX N/A
- Revenue Growth
- REPL N/A
- MAX 64.86
- 52 Week Low
- REPL $2.68
- MAX $7.33
- 52 Week High
- REPL $17.00
- MAX $20.91
- Technical
- Relative Strength Index (RSI)
- REPL 76.27
- MAX 67.91
- Support Level
- REPL $7.69
- MAX $10.73
- Resistance Level
- REPL $10.85
- MAX $13.25
- Average True Range (ATR)
- REPL 0.70
- MAX 0.47
- MACD
- REPL 0.43
- MAX 0.16
- Stochastic Oscillator
- REPL 89.86
- MAX 79.97
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.